NeoStem, Inc.’s subsidiary, Progenitor Cell Therapy (PCT), has expanded its manufacturing partnership with ImmunoCellular Therapeutics for cGMP and development services for ImmunoCellular’s dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, which is in Phase I development for recurrent glioblastoma multiforme (GBM). PCT also manufactured Phase II clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-...